» Articles » PMID: 28656000

Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2017 Jun 29
PMID 28656000
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Protein Kinase D3 (PRKD3) functions as an important oncogenic driver in invasive breast cancer, which is the leading cause of women mortality. However, PRKD3 regulating network is largely unknown. In this study, we systematically explored PRKD3 regulating networks via investigating phosphoproteome, interactome and transcriptome to uncover the molecular mechanism of PRKD3 in invasive breast cancer. Using iTRAQ, 270 proteins were identified as PRKD3 regulated phosphoproteins from 4619 phosphosites matching 3666 phosphopeptides from 2016 phosphoproteins with p-value <0.005. Transcriptome analysis using affymetrix microarray identified 45 PRKD3 regulated genes, in which 20 genes were upregulated and 25 genes were downregulated with p-value <0.005 upon silencing . Using Co-IP in combination of MS identification, 606 proteins were identified to be PRKD3 interacting proteins from 2659 peptides. Further network analysis of PRKD3 regulated phosphoproteins, interacting proteins and regulated genes, reveals 19 hub nodes, including ELAVL1, UBC and BRCA1. UBC was recognized as the most common hub node in PRKD3 regulating networks. The enriched pathway analysis reveals that PRKD3 regulates pathways contributing to multiple cancer related events, including cell cycle, migration and others. Enrichment of cell cycle and cell mobility related pathways across PRKD3 networks, explained the observations that depletion of oncogenic PRKD3 led to alternation of cell cycle and decrease of cell migration ability. Taken together, our current study provided valuable information on the roles as well as the molecular mechanisms of PRKD3 in invasive breast cancer.

Citing Articles

Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes.

Park J, Pena-Tauber A, Talozzi L, Greicius M, Guen Y Nat Commun. 2025; 16(1):2064.

PMID: 40021682 PMC: 11871019. DOI: 10.1038/s41467-025-57315-6.


Transcriptome Analysis Suggests PKD3 Regulates Proliferative Glucose Metabolism, Calcium Homeostasis and Microtubule Dynamics After MEF Spontaneous Immortalization.

Loaiza-Moss J, Braun U, Leitges M Int J Mol Sci. 2025; 26(2).

PMID: 39859313 PMC: 11765705. DOI: 10.3390/ijms26020596.


Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.

Li J, Fang K, Choppavarapu L, Yang K, Yang Y, Wang J Clin Epigenetics. 2021; 13(1):175.

PMID: 34535185 PMC: 8447690. DOI: 10.1186/s13148-021-01167-6.


Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis.

Hulverson M, Choi R, Vidadala R, Whitman G, Vidadala V, Ojo K ACS Infect Dis. 2021; 7(5):1200-1207.

PMID: 33565854 PMC: 8559537. DOI: 10.1021/acsinfecdis.0c00803.


The oncogenic role of protein kinase D3 in cancer.

Liu Y, Song H, Zhou Y, Ma X, Xu J, Yu Z J Cancer. 2021; 12(3):735-739.

PMID: 33403031 PMC: 7778554. DOI: 10.7150/jca.50899.


References
1.
Doppler H, Bastea L, Borges S, Spratley S, Pearce S, Storz P . Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration. PLoS One. 2014; 9(5):e98090. PMC: 4026536. DOI: 10.1371/journal.pone.0098090. View

2.
Hao Q, McKenzie R, Gan H, Tang H . Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res. 2013; 33(2):393-9. View

3.
LaValle C, George K, Sharlow E, Lazo J, Wipf P, Wang Q . Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):183-92. PMC: 2947595. DOI: 10.1016/j.bbcan.2010.05.003. View

4.
Shigemizu D, Hu Z, Hung J, Huang C, Wang Y, DeLisi C . Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012; 8(2):e1002347. PMC: 3276504. DOI: 10.1371/journal.pcbi.1002347. View

5.
Borges S, Perez E, Thompson E, Radisky D, Geiger X, Storz P . Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol Cancer Ther. 2015; 14(6):1306-16. PMC: 4458391. DOI: 10.1158/1535-7163.MCT-14-0945. View